Related Experiment Video

Updated: Apr 9, 2026

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
08:46

Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms

Published on: December 9, 2015

11.3K

Leveraging drug-specific genes to identify sensitizers for resistant cancer cell lines

G Pepe1, E Valentini2, R Appierdo2,3

  • 1Department of Biology, University of Rome Tor Vergata, Rome, Italy. gerardo.pepe@uniroma2.it.

Cell Death Discovery
|April 7, 2026
PubMed

Insights

This study identifies chaetocin as a compound that can reverse cancer drug resistance by altering gene expression. It enhances the effectiveness of existing cancer therapies when used in combination treatments.

Area of Science:

  • Oncology
  • Computational Biology
  • Pharmacology

Background:

  • Therapeutic resistance is a significant challenge in cancer treatment, often driven by cancer cells altering their gene expression to survive chemotherapy.
  • Identifying strategies to overcome this resistance is crucial for improving patient outcomes.

Purpose of the Study:

  • To develop and validate a computational-experimental approach for discovering compounds that can reverse cancer drug resistance.
  • To identify specific compounds that can re-sensitize resistant cancer cells to existing therapies.

Main Methods:

  • Integrated Drug-Specific Genes (DSGs) with Connectivity Map (CMap) data to predict compounds reversing resistance phenotypes.
  • Prioritized candidate compounds based on their predicted ability to normalize DSG expression.
  • Experimentally validated the top-ranked compound, chaetocin, in combination with BMS-345541 and Vorinostat in resistant cell lines (HeLa and NCI-H1299).

Main Results:

  • In silico analysis identified chaetocin as a promising drug resistance sensitizer.
  • Experimental validation confirmed chaetocin enhanced the efficacy of BMS-345541 in HeLa cells and Vorinostat in NCI-H1299 cells.
  • Combination therapies significantly reduced cell viability, increased apoptosis, and induced G2/M cell cycle arrest compared to monotherapies.

Conclusions:

  • DSG-guided transcriptional reversal is a viable strategy for overcoming therapeutic resistance in oncology.
  • Chaetocin demonstrates potential as a resistance-modulating agent, restoring drug sensitivity in resistant cancer models.
  • The epigenetic activity of chaetocin positions it as a promising partner in combination cancer therapies.

More Related Videos

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids08:52

Profiling Sensitivity to Targeted Therapies in EGFR-Mutant NSCLC Patient-Derived Organoids

Published on: November 22, 2021

4.7K
Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

7.7K

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
69
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
88
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K